| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce384cea17765179fd01cd5c80f294ef |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
| filingDate |
2003-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e700b1c2703dcb39965bdf8620e5345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f54ff9c34a7c17507511f77c15da6f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29ad9b2113aa3a586136a270b45da6ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e517c227f849a2aaeaf5da76cbe13fed |
| publicationDate |
2003-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2516318-A1 |
| titleOfInvention |
Use of glycosaminoglycans such as heparin for the treatment of respiratory disorders such as copd |
| abstract |
A glycosaminoglycan or a physiologically acceptable salt thereof, which has an average molecule weight of from 8 to 40 kd can be used to treat chronic airflow limitation (CAL). The glycosaminoglycan or salt is typically inhaled. |
| priorityDate |
2002-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |